The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Cancer stem cells in osteosarcoma
Open accessAbstract
Osteosarcoma is the most common primary bone tumour in children and adolescents and advanced osteosarcoma patients with evidence of metastasis share a poor prognosis. Osteosarcoma frequently gains resistance to standard therapies highlighting the need for improved treatment regimens and identification of novel therapeutic targets. Cancer stem cells (CSC) represent a sub-type of tumour cells attributed to critical steps in cancer including tumour propagation, therapy resistance, recurrence and in some cases metastasis. Recent published work demonstrates evidence of cancer stem cell phenotypes in osteosarcoma with links to drug resistance and tumorigenesis. In this review we will discuss the commonly used isolation techniques for cancer stem cells in osteosarcoma as well as the identified biochemical and molecular markers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This seed and soil phenomenon is driven by a microenvironment that modulates osteosarcoma cell behaviour and facilitates proliferation, quiescence, invasion, migration, and drug resistance 15,51,52,53 and contributes to their intrinsic heterogeneity 54,55 .”
From Osteosarcoma (2022) · cites this paper as [52]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
Patel, A. P., Tirosh, I., Trombetta, J. J., Shalek, A. K., Gillespie, S. M., Wakimoto, H., Cahill, D. P., Nahed, B. V., Curry, W. T., Martuza, R. L., et al. (2014) · Science · doi:10.1126/science.1254257 · Cited by 5,063
Clarke, M. F., Dick, J. E., Dirks, P. B., Eaves, C., Jamieson, C., Jones, D. L., Visvader, J., Weissman, I. L., & Wahl, G. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-3126 · Cited by 3,124
Tumour evolution inferred by single-cell sequencing
Navin, N., Kendall, J., Troge, J., Andrews, P., Rodgers, L., McIndoo, J., Cook, K., Stepansky, A., Levy, D., Esposito, D., et al. (2011) · Nature · doi:10.1038/nature09807 · Cited by 2,598
Cancer stem cell definitions and terminology: the devil is in the details
Valent, P., Bonnet, D. A., Maria, R. D., Lapidot, T., Copland, M., Melo, J. V., Chomienne, C., Ishikawa, F., Schuringa, J. J., Stassi, G., et al. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3368 · Cited by 720
Mechanisms of Stem Cell Self-Renewal
He, S., Nakada, D., & Morrison, S. J. (2009) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.042308.113248 · Cited by 644
Stem-Like Cells in Bone Sarcomas: Implications for Tumorigenesis
Gibbs, C. P., Kukekov, V. G., Reith, J. D., Tchigrinova, O., Suslov, O. N., Scott, E. W., Ghivizzani, S. C., Ignatova, T. N., & Steindler, D. A. (2005) · Neoplasia · doi:10.1593/neo.05394 · Cited by 492
Tirino, V., Desiderio, V., Paino, F., ROSA, A. D., Papaccio, F., Noce, M. L., Laino, L., Francesco, F. D., & Papaccio, G. (2012) · The FASEB Journal · doi:10.1096/fj.12-218222 · Cited by 391
Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency
Kovac, M., Blattmann, C., Ribi, S., Smida, J., Mueller, N. S., Engert, F., Castro-Giner, F., Weischenfeldt, J., Kovacova, M., Krieg, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms9940 · Cited by 353
Detection and Characterization of CD133+ Cancer Stem Cells in Human Solid Tumours
Tirino, V., Desiderio, V., d’Aquino, R., Francesco, F. D., Pirozzi, G., Galderisi, U., Cavaliere, C., Rosa, A. D., & Papaccio, G. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003469 · Cited by 292
Kim, K., Lee, H. W., Lee, H., Kim, S. C., Seo, Y. J., Chung, W., Eum, H. H., Nam, D., Kim, J., Joo, K. M., et al. (2015) · Genome biology · doi:10.1186/s13059-015-0692-3 · Cited by 269
Adhikari, A. S., Agarwal, N. A., Wood, B. M., Porretta, C. P., Ruiz, B. A., Pochampally, R. R., & Iwakuma, T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3463 · Cited by 261
Sox2 antagonizes the Hippo pathway to maintain stemness in cancer cells
Basu-Roy, U., Bayin, N. S., Rattanakorn, K., Han, E. J., Placantonakis, D. G., Mansukhani, A., & Basilico, C. (2015) · Nature Communications · doi:10.1038/ncomms7411 · Cited by 257
Sox2 maintains self renewal of tumor-initiating cells in osteosarcomas
Basu-Roy, U., Seo, E., Ramanathapuram, L. V., Rapp, T. B., Perry, J. A., Orkin, S. H., Mansukhani, A., & Basilico, C. (2011) · Oncogene · doi:10.1038/onc.2011.405 · Cited by 239
Hiley, C. T., de Bruin, E. C., McGranahan, N., & Swanton, C. (2014) · Genome biology · doi:10.1186/s13059-014-0453-8 · Cited by 233
Osteosarcoma: Cells‐of‐Origin, Cancer Stem Cells, and Targeted Therapies
Abarrategi, A., Tornín, J., Martínez-Cruzado, L., Hamilton, A., Martínez‐Campos, E., Rodrigo, J. P., González, M. V., Baldini, N., Garcı́a-Castro, J., & Rodrı́guez, R. (2016) · Stem Cells International · doi:10.1155/2016/3631764 · Cited by 211
Human primary bone sarcomas contain CD133 + cancer stem cells displaying high tumorigenicity in vivo
Tirino, V., Desiderio, V., Paino, F., ROSA, A. D., Papaccio, F., Fazioli, F., Pirozzi, G., & Papaccio, G. (2011) · The FASEB Journal · doi:10.1096/fj.10-179036 · Cited by 201
Sphere-forming stem-like cell populations with drug resistance in human sarcoma cell lines
Honoki (2009) · International Journal of Oncology · doi:10.3892/ijo_00000265 · Cited by 166
Hedgehog signaling induces osteosarcoma development through Yap1 and H19 overexpression
Chan, L. H., Wang, W., Yeung, W. W., Deng, Y., Yuan, P., & Mak, K. K. (2013) · Oncogene · doi:10.1038/onc.2013.433 · Cited by 164
Honoki (2010) · Oncology Reports · doi:10.3892/or_00000885 · Cited by 143
TGF-β Signaling in Bone Remodeling and Osteosarcoma Progression
Lamora, A., Talbot, J., Mullard, M., Royer, B. B.-L., Rédiní, F., & Verrecchia, F. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm5110096 · Cited by 141
Notch Activation as a Driver of Osteogenic Sarcoma
Tao, J., Jiang, M., Jiang, L., Salvo, J. S., Zeng, H., Dawson, B., Bertin, T., Rao, P. H., Chen, R., Donehower, L. A., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.07.023 · Cited by 137
Tumor initiating potential of side population cells in human gastric cancer
Saikawa (2009) · International Journal of Oncology · doi:10.3892/ijo_00000248 · Cited by 129
Wang, L., Park, P., Zhang, H., Marca, F. L., & Lin, C.-Y. J. (2010) · International Journal of Cancer · doi:10.1002/ijc.25331 · Cited by 126
Murase, M., Kano, M., Tsukahara, T., Takahashi, A., Torigoe, T., Kawaguchi, S., Kimura, S., Wada, T., Uchihashi, Y., Kondo, T., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605330 · Cited by 123
The Side Population of Ovarian Cancer Cells Is a Primary Target of IFN-α Antitumor Effects
Moserle, L., Indraccolo, S., Ghisi, M., Frasson, C., Fortunato, E., Canevari, S., Miotti, S., Tosello, V., Zamarchi, R., Corradin, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6341 · Cited by 118
Martins‐Neves, S. R., Lopes, Á. O., do Carmo, A., Paiva, A. A., Simões, P. C. P. S., Abrunhosa, A., & Gomes, C. M. F. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-139 · Cited by 117
Chemotherapy induces stemness in osteosarcoma cells through activation of Wnt/β-catenin signaling
Martins‐Neves, S. R., Paiva‐Oliveira, D. I., Wijers‐Koster, P. M., Abrunhosa, A., Ribeiro, C., Bovée, J. V. M. G., Cleton-Jansen, A., & Gomes, C. M. F. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.11.013 · Cited by 113
Zhang, H., Wu, H., Zheng, J., Yu, P., Xu, L., Jiang, P., Gao, J., Wang, H., & Zhang, Y. (2012) · Stem Cells · doi:10.1002/stem.1298 · Cited by 112
Perspectives on cancer stem cells in osteosarcoma
Basu-Roy, U., Basilico, C., & Mansukhani, A. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.05.028 · Cited by 105
MiR-26a inhibits stem cell-like phenotype and tumor growth of osteosarcoma by targeting Jagged1
Lu, J., Song, G., Tang, Q., Yin, J., Zou, C., Zhao, Z. Q., Xie, X., Xu, H., Huang, G., Wang, J., et al. (2016) · Oncogene · doi:10.1038/onc.2016.194 · Cited by 91
Osteosarcoma Stem Cells Have Active Wnt/β‐catenin and Overexpress SOX2 and KLF4
Martins‐Neves, S. R., Corver, W. E., Paiva‐Oliveira, D. I., van den Akker, B. E. W. M., Briaire-de-Bruijn, I. H., Bovée, J. V. M. G., Gomes, C. M. F., & Cleton-Jansen, A. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.25179 · Cited by 84
Tsuchida, R., Das, B., Yeger, H., Koren, G., Shibuya, M., Thorner, P. S., Baruchel, S., & Malkin, D. M. (2008) · Oncogene · doi:10.1038/onc.2008.38 · Cited by 77
The marrow niche controls the cancer stem cell phenotype of disseminated prostate cancer
Shiozawa, Y., Berry, J. E., Eber, M. R., Jung, Y., Yumoto, K., Cackowski, F. C., Yoon, H. J., Parsana, P., Mehra, R., Wang, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9251 · Cited by 73
Fujiwara, T., Katsuda, T., Hagiwara, K., Kosaka, N., Yoshioka, Y., Takahashi, R., Takeshita, F., Kubota, D., Kondo, T., Ichikawa, H., et al. (2013) · Stem Cells · doi:10.1002/stem.1618 · Cited by 72
Cisplatin selects for stem-like cells in osteosarcoma by activating Notch signaling
Yu, L., Fan, Z., Fang, S., Yang, J., Gao, T., Simões, B. M., Eyre, R., Guo, W., & Clarke, R. B. (2016) · Oncotarget · doi:10.18632/oncotarget.8849 · Cited by 72
Methods for Cancer Stem Cell Detection and Isolation
Tirino, V., Desiderio, V., Paino, F., Papaccio, G., & ROSA, M. D. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-815-3_32 · Cited by 63
Side population cells isolated from human osteosarcoma are enriched with tumor‐initiating cells
Yang, M. H., Yan, M., Zhang, R., Li, J., & Luo, Z. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.02028.x · Cited by 60
CD133 expression in osteosarcoma and derivation of CD133+ cells
Li, J., Zhong, X., Li, Z., CAI, J.-F., ZOU, L., LI, J.-M., Yang, T., & Liu, W. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2012.1231 · Cited by 55
ALDH Activity Correlates with Metastatic Potential in Primary Sarcomas of Bone
Greco, N., Schott, T., Mu, X., Rothenberg, A. C., Voigt, C., McGough, R. L., Goodman, M. A., Huard, J., & Weiss, K. R. (2014) · Journal of Cancer Therapy · doi:10.4236/jct.2014.54040 · Cited by 55
He, A., Qi, W., Huang, Y., FENG, T., Chen, J., Sun, Y., Shen, Z., & Yao, Y. (2012) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2012.603 · Cited by 54
CD271+ Osteosarcoma Cells Display Stem-Like Properties
Tian, J., Li, X., Si, M., Liu, T., & Li, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098549 · Cited by 54
Enrichment of osteosarcoma stem cells by chemotherapy
Tang, Q., Liang, Y., Xie, X., Yin, J., Zou, C., Zhao, Z., Shen, J., & Wang, J. (2011) · 癌症：英文版 · doi:10.5732/cjc.011.10127 · Cited by 47
Enrichment of human osteosarcoma stem cells based on hTERT transcriptional activity
Yu, L., Liu, S., Zhang, C., Zhang, B., Simões, B. M., Eyre, R., Liang, Y., Yan, H., Wu, Z., Guo, W., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1554 · Cited by 34
Deciphering intratumor heterogeneity using cancer genome analysis
Ryu, D., Joung, J., Kim, N. K. D., Kim, K., & Park, W. (2016) · Human Genetics · doi:10.1007/s00439-016-1670-x · Cited by 28
Bone sarcomas: pathogenesis and new therapeutic approaches
Heymann, D., & Rédiní, F. (2011) · IBMS BoneKEy · doi:10.1138/20110531 · Cited by 26
Self-citationLung metastasis 21 years after initial diagnosis of osteosarcoma: a case report
Halldorsson, A., Brooks, S., Montgomery, S., & Graham, S. C. (2009) · Journal of Medical Case Reports · doi:10.1186/1752-1947-3-9298 · Cited by 23
Penfornis, P., Cai, D. Z., Harris, M. R., Walker, R., Licini, D. J., Fernandes, J. D., Orr, G., Koganti, T., Hicks, C., Induru, S., et al. (2014) · Cancer Medicine · doi:10.1002/cam4.249 · Cited by 16
Cited by
Sorted by citations
Beird, H. C., Bielack, S. S., Flanagan, A. M., Gill, J., Heymann, D., Janeway, K. A., Livingston, J. A., Roberts, R. D., Strauss, S. J., & Gorlick, R. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00409-y · Cited by 660
Self-citationCancer stem cells: advances in knowledge and implications for cancer therapy
Chu, X., Tian, W., Ning, J., Xiao, G., Zhou, Y., Wang, Z., Zhai, Z., Tanzhu, G., Yang, J., & Zhou, R. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01851-y · Cited by 656
Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs
Chen, C., Xie, L., Ren, T., Huang, Y., Xu, J. H., & Guo, W. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.12.024 · Cited by 587
Molecular Biology of Osteosarcoma
Czarnecka, A. M., Synoradzki, K. J., Firlej, W., Bartnik, E., Sobczuk, P., Fiedorowicz, M., Grieb, P., & Rutkowski, P. L. (2020) · Cancers · doi:10.3390/cancers12082130 · Cited by 343
Sarcoma treatment in the era of molecular medicine
Grünewald, T. G., Alonso, M., Avnet, S., Banito, A., Burdach, S., Cidre‐Aranaz, F., Di Pompo, G., Distel, M., Dorado‐Garcia, H., Garcia‐Castro, J., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201911131 · Cited by 319
Self-citation
Metadata
- Authors
- Brown, H. K., Tellez-Gabriel, M., & Heymann, D.
- Affiliations
- Inserm (FR)
- Corresponding author
- Brown, Hannah K.
- Heymann, Dominique
- ORCID
- Heymann, Dominique
- Venue
- Cancer Letters
- Publisher
- Elsevier BV
- Published
- 2017-02
- Volume
- 386
- Pages
- 189-195
- ISSN
- 0304-3835 (ISSN-L)
- OpenAlex
- W2551783204
- Cited by
- 303
- References
- 47
- Citations by year
- 2026: 12 · 2025: 23 · 2024: 43 · 2023: 33 · 2022: 41 · 2021: 49 · 2020: 50 · 2019: 34 · 2018: 10 · 2017: 8
- FWCI
- 1.74
- Type
- journal article
- Language
- en
- Open access
- green
- inserm.hal.science
- Licence
- Locations
- Cancer Letters (publishedVersion)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- HAL (submittedVersion, other-oa)
- Funders
- Bone Cancer Research Trust (144681)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Keywords
- osteosarcoma, cancer stem cells, drug resistance, carcinogenesis, metastasis, cancer stem cell isolation, molecular markers, therapeutic target, pediatric bone tumors
- MeSH terms
- Animals, Antineoplastic Agents, Bone Neoplasms, Cell Separation, Humans, Phenotype, Osteosarcoma, Biomarkers, Tumor, Neoplastic Stem Cells, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
